5-pyrimidinecarboxamide Uses, Dosage, Side Effects and more
5-pyrimidinecarboxamide is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of 5-pyrimidinecarboxamide in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)).
| Trade Name | 5-pyrimidinecarboxamide |
| Generic | Cerdulatinib |
| Cerdulatinib Other Names | 4-(cyclopropylamino)-2-((4-(4-(ethanesulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide, 5-pyrimidinecarboxamide, 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)-1-piperazinyl)phenyl)amino)-, Cerdulatinib |
| Type | |
| Formula | C20H27N7O3S |
| Weight | Average: 445.54 Monoisotopic: 445.189608931 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
